Introduction: A New Frontier in Pulmonary Therapeutics
In a landmark move for the pharmaceutical industry, Aptar Pharma, a global leader in drug delivery systems, has announced a strategic three-year research partnership with Macquarie University in Australia. This collaboration is set to redefine the boundaries of pulmonary drug delivery, specifically targeting the complex challenge of administering biologic medicines via inhalation. By leveraging Aptar’s proprietary Orbital™ dry powder inhaler (DPI) platform, the partnership aims to bridge the gap between formulation science and device engineering, potentially unlocking new pathways for treating systemic diseases through the lungs.
The Core Partnership: Bridging Academic Rigor and Industry Innovation
The collaboration brings together the industrial expertise of Aptar Pharma—renowned for its advanced delivery technologies—and the academic excellence of Macquarie University. Over the next three years, the joint research team will conduct a deep-dive investigation into the interplay between formulation variables and aerosol performance.
The project is centered on the Orbital™ DPI platform, a device specifically engineered to handle high-payload dry powder formulations. Traditionally, delivering large doses of biologics via inhalation has been hampered by stability, dispersion, and particle size limitations. By scrutinizing how different engineered, blended, and combined powder formulations interact with the Orbital™ platform, the researchers aim to generate robust data sets that will inform future drug-device combinations.
Chronology of Progress: Building Momentum in Inhalation Science
The announcement of the Macquarie University partnership follows a period of rapid development and strategic expansion for Aptar Pharma.
- September 2026 (Early Month): Aptar Pharma announced a separate, pivotal partnership with French biotech firm Aceso Therapeutics. The collaboration focuses on advancing ACT-101, an inhalable antisense oligonucleotide (ASO) therapy designed to address the root causes of cystic fibrosis.
- Late September 2026: Aptar formally unveiled the three-year research initiative with Macquarie University, signaling a broader commitment to the foundational science of high-dose dry powder delivery.
- Ongoing Integration: Through its specialized inhalation development services division, Nanopharm, Aptar continues to integrate these academic and commercial partnerships into a unified strategy, positioning itself as the primary infrastructure provider for the next generation of inhaled therapies.
Supporting Data: Why the Lungs?
The interest in pulmonary delivery for non-respiratory diseases is not misplaced; it is rooted in human physiology. The pulmonary system offers a massive, highly vascularized surface area—the alveolar region—which allows for rapid absorption directly into the systemic circulation.
For biologics—which are often susceptible to degradation in the gastrointestinal tract or require frequent, painful injections—the lungs present an attractive, non-invasive alternative. However, delivering these molecules effectively requires precision. The particles must be of an optimal size to reach the deep lungs, stable enough to survive the delivery process, and concentrated enough to meet therapeutic thresholds without overwhelming the device.
The partnership will utilize this research to develop advanced Computational Fluid Dynamics (CFD) models. These models are crucial, as they allow scientists to visualize aerosol behavior and particle transport in ways that were previously inaccessible through physical testing alone. By mapping how different powder formulations behave under the aerodynamic stress of the Orbital™ device, the team will create a digital roadmap for faster, more predictable drug development.
Official Perspectives: The Strategic Vision
Industry leaders have framed this partnership as a vital step toward maturing the inhaled biologic market.
Guillaume Brouet, Aptar’s Vice President of Scientific Affairs, emphasized the inherent challenges of the field. "Biologic medicines represent a promising area of pharmaceutical development, yet significant challenges remain in translating their potential into effective inhaled therapies," Brouet stated. He noted that the partnership is not merely about testing a device, but about creating a new scientific paradigm. "By combining academic and industry expertise, this programme will help advance scientific understanding of high-dose dry powder delivery and support the development of future inhaled biologic medicines."
From the perspective of Macquarie University, the partnership represents an opportunity to apply theoretical fluid dynamics and particle engineering to real-world medical challenges, ensuring that academic breakthroughs move from the laboratory bench to the patient bedside.
Implications for the Future of Healthcare
The implications of this collaboration are far-reaching, touching on several key areas of medical development:
1. Moving Beyond Localized Treatment
Historically, inhalers were synonymous with asthma or COPD management—localized treatments for localized inflammation or bronchoconstriction. The success of this research could normalize the use of inhalers for systemic conditions, including autoimmune disorders, oncology, and genetic diseases where biologics are the standard of care.
2. Improving Patient Adherence
One of the most significant burdens for patients undergoing biologic therapy is the requirement for regular injections or intravenous infusions, often requiring clinical visits. An inhalable alternative—one that is portable, patient-friendly, and effective—could drastically increase adherence rates, reduce the burden on healthcare systems, and improve the quality of life for patients.
3. The Role of Computational Fluid Dynamics (CFD)
The shift toward predictive modeling in drug delivery is a trend that this partnership is helping to accelerate. By developing sophisticated CFD models, Aptar and Macquarie are setting a new standard for regulatory submissions. Regulators are increasingly looking for evidence-based, data-driven approaches to device performance, and the output of this three-year study will likely become a benchmark for future device validation processes.
4. Synergy with Existing Portfolios
The timing of this partnership is strategic. With the concurrent work on ACT-101 for cystic fibrosis via Nanopharm, Aptar is building an ecosystem of inhalation technologies. The insights gained from the Macquarie study will likely feed back into the development of other assets, creating a "virtuous cycle" of innovation where fundamental research informs commercial product pipelines.
Conclusion: A Catalyst for Change
As the pharmaceutical industry shifts toward more complex, large-molecule therapeutics, the delivery mechanisms must evolve in lockstep. The partnership between Aptar Pharma and Macquarie University is more than a standard industry-academia collaboration; it is a dedicated effort to overcome the mechanical and physical barriers that have historically kept inhaled biologics in the realm of "promising potential" rather than "clinical reality."
By focusing on the fundamental science of high-payload delivery, the partnership is laying the groundwork for a future where life-changing therapies are as easy to administer as a breath of air. As the project unfolds over the next three years, the data generated will likely influence not only the design of the Orbital™ platform but the entire landscape of respiratory drug development for years to come.
Disclaimer: This report is based on information provided by the companies and research institutions involved. For further updates on the progress of the CFD modeling or specific breakthroughs in formulation design, interested parties should monitor the official corporate channels of Aptar Pharma and the research publications emerging from Macquarie University.
About the Author
